Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin for the Prevention of Hypoglycemia in MCADD
NCT06067802Phase 2Withdrawn
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of triheptanoin in medium-chain acyl-CoA dehydrogenase deficiency. Planned start Aug 2026; status: withdrawn.
02
Drugs
triheptanoin
03
Conditions
medium-chain acyl-CoA dehydrogenase deficiency
Beyond the preview
Go deeper on NCT06067802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067802.